Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | GABRD | O14764 | 1/20 | 0.31 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.31 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.31 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15096488 | 0.79 | — | — | |
| SCHEMBL2186034 | 0.79 | — | — | |
| SCHEMBL23118092 | 0.75 | GABRD (0.34) | SLC6A2SLC6A4SLC6A3GABRDGABRA1 | |
| SCHEMBL23118091 | 0.75 | GABRD (0.34) | SLC6A2SLC6A4SLC6A3GABRDGABRA1 | |
| SCHEMBL4530377 | 0.74 | AR (0.34) | SLC6A2SLC6A4SLC6A3GABRDGABRA1 | |
| SCHEMBL28420437 | 0.73 | GAA (0.36) | ALDH1A1KDM4EMEN1MAPTKMT2A | |
| SCHEMBL28420438 | 0.73 | GAA (0.36) | ALDH1A1KDM4EMEN1MAPTKMT2A | |
| SCHEMBL5569537 | 0.73 | MGAT2 (0.37) | SLC6A2SLC6A4SLC6A3ALDH1A1TSHR | |
| SCHEMBL6972157 | 0.72 | GAA (0.38) | ALDH1A1KDM4EMAPTTHRB | |
| SCHEMBL31283271 | 0.72 | AR (0.36) | SLC6A2SLC6A4SLC6A3GABRDGABRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322847-A1 | NEUROACTIVE STEROIDS AND THEIR METHODS OF USE | SAGE THERAPEUTICS, INC. | 2023-10-12 | — | — | US | disclosed |
| WO-2021068820-A1 | ALKENE-CONTAINING CARBOXYLATE COMPOUND AND USE THEREOF | 沈阳中化农药化工研发有限公司 | 2021-04-15 | — | — | WO | disclosed |
| US-20090075980-A1 | Pyrazolopyridines and Analogs Thereof | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2009-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090075980-A1 | Pyrazolopyridines and Analogs Thereof | IL4, IL4I1, IL2 | RPS6KB1 3150/4885HRH3 386/4885SLC6A2 2080/4885 |
| US-20230322847-A1 | NEUROACTIVE STEROIDS AND THEIR METHODS OF USE | NR3C2, MC2R, NR3C1 | RPS6KB1 709/4885HRH3 573/4885SLC6A2 95/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.